Other biomarker chemokines, in addition to CXCL4, have been associated with interstitial lung disease (ILD), which develops in 65–85% of SSc patients and is characterized by endothelial dysfunction, extracellular matrix deposition and subsequent pulmonary fibrosis [72]. This evidence concerns the gene PF4 and systemic sclerosis.